Evidence map›Paper›PMID 33016217›Full record

ArticlemAbs

On-column disulfide bond formation of monoclonal antibodies during Protein A chromatography eliminates low molecular weight species and rescues reduced antibodies.

Zhijun Tan, Vivekh Ehamparanathan, Tingwei Ren, Peifeng Tang, Laurel Hoffman, June Kuang, Peiran Liu, Chao Huang, Cheng Du, Li Tao and 5 more

Open access · goldAbstract readVideo-Audio Media
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

Zhijun TanGlobal Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA.
Vivekh EhamparanathanGlobal Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA.
Tingwei RenGlobal Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA.
Peifeng TangGlobal Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA.
Laurel HoffmanGlobal Product Development and Supply, Bristol-Myers Squibb Company , Pennington, NJ, USA.
June KuangGlobal Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA.
Peiran LiuGlobal Product Development and Supply, Bristol-Myers Squibb Company , Pennington, NJ, USA.
Chao HuangGlobal Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA.
Cheng DuGlobal Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA.ORCID 0000-0002-8882-2513
Li TaoGlobal Product Development and Supply, Bristol-Myers Squibb Company , Pennington, NJ, USA.
Letha ChemmalilGlobal Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA.
Angela LewandowskiGlobal Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA.
Sanchayita GhoseGlobal Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA.
Zheng Jian LiGlobal Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA.ORCID 0000-0002-1941-4145
Shijie LiuDepartment of Paper and Bioprocess Engineering, The State University of New York College of Environmental Science and Forestry , Syracuse, NY, USA.ORCID 0000-0003-3286-8958
Bristol-Myers Squibb (Germany) · DEState University of New York · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Disulfide bond reduction, which commonly occurs during monoclonal antibody (mAb) manufacturing processes, can result in a drug substance with high levels of low molecular weight (LMW) species that may fail release specifications because the drug's safety and the efficiency may be affected by the presence of this material. We previously studied disulfide reoxidation of mAbs and demonstrated that disulfide bonds could be reformed from the reduced antibody via redox reactions under an optimal redox condition on Protein A resin. The study here implements a redox system in a manufacturing setting to rescue the reduced mAb product and to further eliminate LMW issues in downstream processing. As such, we incorporate the optimized redox system as one of the wash buffers in Protein A chromatography to enable an on-column disulfide reoxidation to form intact antibody in vitro. Studies at laboratory scale (1 cm (ID) x 20 cm (Height), MabSelect SuRe LX) and pilot scale (30 cm (ID) x 20 cm (Height), MabSelect SuRe LX) were performed to demonstrate the effectiveness and robustness of disulfide formation with multiple mAbs using redox wash on Protein A columns. By applying this rescue strategy using ≤50 g/L-resin loading, the intact mAb purity was improved from <5% in the Protein A column load to >90% in the Protein A column elution with a product yield of >90%. Studies were also done to confirm that adding the redox wash has no negative impact on process yield or impurity removal or product quality. The rescued mAbs were confirmed to form complete interchain disulfide bonds, exhibiting comparable biophysical properties to the reference material. Furthermore, since the redox wash is followed by a bridging buffer wash before the final elution, no additional burden is involved in removing the redox components during the downstream steps. Due to its ease of implementation, significant product purity improvement, and minimal impact on other product quality attributes, we demonstrate that the on-column reoxidation using a redox system is a powerful, simple, and safe tool to recover reduced mAb during manufacturing. Moreover, the apparent benefits of using a high-pH redox wash may further drive the evolution of Protein A platform processes.

Indexed as

Chromatography, AffinityAnimalsAntibodies, MonoclonalCHO CellsCricetulusDisulfidesOxidation-ReductionStaphylococcal Protein AAntibodies, MonoclonalDisulfidesStaphylococcal Protein AAntibodydisulfide bondlow molecular weightProtein A chromatographyredox/reduction/reoxidation

Identifiers

PMID33016217
PMCPMC7577237
OpenAlexW3091382535

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.